Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYPQT4)

• Drug Name: 4SCAR19 and 4SCAR123 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
B-cell lymphoma	2A86	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMYPQT4

Molecule-Related Drug Atlas

Drug(s) Targeting B-lymphocyte surface antigen B4 (CD19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tisagenlecleucel	DMM9BJD	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Axicabtagene ciloleucel	DMYHN59	Diffuse large B-cell lymphoma	2A81	Approved	[4]
Lisocabtagene maraleucel	DMP45ME	Large B-cell lymphoma	2A81	Approved	[5]
Inebilizumab	DMI0RHA	Neuromyelitis optica spectrum disorder	8E4A.0	Approved	[6]
Tecartus	DMYQCWT	Mantle cell lymphoma	2A85.5	Approved	[7]
Loncastuximab tesirine	DMXSVGI	Diffuse large B-cell lymphoma	2A81	Approved	[8]
Obexelimab	DMVIC4J	IgG4 related disease	4A43.0	Phase 3	[9]
MOR-208	DMDQOWT	Diffuse large B-cell lymphoma	2A81	Phase 2/3	[10]
CART-19	DMST3FM	Acute lymphoblastic leukaemia	2A85	Phase 2/3	[11]

Drug(s) Targeting Interleukin 3 receptor alpha (IL3RA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tagraxofusp	DM9HQ5U	Acute myeloid leukaemia	2A60	Approved	[12]
CD123/CLL1 CAR-T Cells	DM45Z3P	Acute myeloid leukaemia	2A60	Phase 2/3	[13]
Talacotuzumab	DMARVFG	Acute myeloid leukaemia	2A60	Phase 2	[14]
MB-102	DMLPNVS	Acute kidney injury	GB60	Phase 2	[14]
Flotetuzumab	DMVR6OM	Acute biphenotypic leukaemia	2B33.4	Phase 2	[14]
SAR440234	DM6M8O4	Acute myeloid leukaemia	2A60	Phase 1/2	[15]
CD123-specific gene-engineered T cells	DMHOWU5	Acute myeloid leukaemia	2A60	Phase 1/2	[16]
CART-123 cells	DM0MCTJ	Acute myeloid leukaemia	2A60	Phase 1/2	[17]
CART-123 cells	DM0MCTJ	Acute myeloid leukaemia	2A60	Phase 1/2	[18]
Anti-CD123-CAR-transduced T cells	DMFV6TY	leukaemia	2A60-2B33	Phase 1/2	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]
Interleukin 3 receptor alpha (IL3RA)	TTENHJ0	IL3RA_HUMAN	CAR-T-Cell-Therapy(Dual specific)	[1]

References

• [1] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [8] Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
• [9] Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
• [10] A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
• [11] ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
• [12] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [13] ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [16] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [17] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
• [18] ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML
• [19] ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies